NO20005357D0 - Sulfonamidholdige indolforbindelser - Google Patents

Sulfonamidholdige indolforbindelser

Info

Publication number
NO20005357D0
NO20005357D0 NO20005357A NO20005357A NO20005357D0 NO 20005357 D0 NO20005357 D0 NO 20005357D0 NO 20005357 A NO20005357 A NO 20005357A NO 20005357 A NO20005357 A NO 20005357A NO 20005357 D0 NO20005357 D0 NO 20005357D0
Authority
NO
Norway
Prior art keywords
hydrogen
ring
represents hydrogen
indole compounds
cyanophenyl
Prior art date
Application number
NO20005357A
Other languages
English (en)
Other versions
NO317299B1 (no
NO20005357L (no
Inventor
Toru Haneda
Akihiko Tsuruoka
Jun-Ichi Kamata
Tadashi Okabe
Keiko Takahashi
Kazumasa Nara
Shinichi Hamaoka
Norihiro Ueda
Takashi Owa
Toshiaki Wakabayashi
Yasuhiro Funahashi
Taro Semba
Naoko Hata
Yuji Yamamoto
Yoichi Ozawa
Naoko Tsukahara
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of NO20005357D0 publication Critical patent/NO20005357D0/no
Publication of NO20005357L publication Critical patent/NO20005357L/no
Publication of NO317299B1 publication Critical patent/NO317299B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20005357A 1999-02-26 2000-10-24 Sulfonamidholdige indolforbindelser, deres anvendelse samt farmasoytiske preparater inneholdende disse NO317299B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP11049870A JP2000247949A (ja) 1999-02-26 1999-02-26 スルホンアミド含有インドール化合物
PCT/JP2000/001071 WO2000050395A1 (en) 1999-02-26 2000-02-24 Sulfonamide-containing indole compounds

Publications (3)

Publication Number Publication Date
NO20005357D0 true NO20005357D0 (no) 2000-10-24
NO20005357L NO20005357L (no) 2000-12-22
NO317299B1 NO317299B1 (no) 2004-10-04

Family

ID=12843091

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005357A NO317299B1 (no) 1999-02-26 2000-10-24 Sulfonamidholdige indolforbindelser, deres anvendelse samt farmasoytiske preparater inneholdende disse

Country Status (17)

Country Link
US (3) US6469043B1 (no)
EP (1) EP1074542B1 (no)
JP (3) JP2000247949A (no)
KR (1) KR100627611B1 (no)
CN (1) CN1132814C (no)
AT (1) ATE325094T1 (no)
AU (1) AU766936B2 (no)
CA (1) CA2327253C (no)
DE (1) DE60027648T2 (no)
DK (1) DK1074542T3 (no)
ES (1) ES2259997T3 (no)
HU (1) HU228787B1 (no)
NO (1) NO317299B1 (no)
NZ (1) NZ507464A (no)
PT (1) PT1074542E (no)
RU (1) RU2208607C2 (no)
WO (1) WO2000050395A1 (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100767000B1 (ko) * 2000-02-03 2007-10-15 에자이 알앤드디 매니지먼트 가부시키가이샤 인테그린 발현 저해제
EP1317260A2 (en) * 2000-08-30 2003-06-11 Signature Bioscience, Inc. Methods for treating tumors using sulfonyl compounds
TWI283575B (en) 2000-10-31 2007-07-11 Eisai Co Ltd Medicinal compositions for concomitant use as anticancer agent
WO2002066073A1 (en) * 2001-02-21 2002-08-29 Eisai C0. Ltd. Method of examining effect of angionegesis inhibitor mediated by the inhibition of integrin expression
TW589181B (en) * 2001-09-05 2004-06-01 Eisai Co Ltd Lymphocytic activation inhibitor and remedial agent for autoimmune disease
EP1433479B8 (en) * 2001-09-05 2008-01-23 Eisai R&D Management Co., Ltd. Appetite-stimulating agents and remedies for anorexia
JP4542783B2 (ja) * 2002-03-05 2010-09-15 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド含有複素環化合物及び血管新生抑制剤とを組み合わせてなる抗腫瘍剤
AU2003237705B2 (en) * 2002-06-05 2009-07-30 F. Hoffmann-La Roche Ag 1-sulfonyl-4-aminoalkoxy indole derivatives as 5-HT6-receptor modulators for the treatment of CNS-disorders
EP1608626A1 (en) 2003-03-28 2005-12-28 Cornell Research Foundation, Inc. Migrastatin analog compositions and uses thereof
WO2004091664A1 (ja) * 2003-04-18 2004-10-28 Eisai Co., Ltd. 細胞質リンゴ酸脱水素酵素阻害剤
US20070037854A1 (en) * 2003-09-10 2007-02-15 Kenji Hayashi Process for preparing sulfonamide-containing indole compounds
RU2336269C2 (ru) * 2003-09-10 2008-10-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Кристаллическое индолсульфонамидное соединение и способ его получения
ATE546157T1 (de) * 2003-11-13 2012-03-15 Sutter West Bay Hospitals Anti-pecam-therapie zur unterdrückung von metastasen
JP5149001B2 (ja) * 2004-05-25 2013-02-20 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ 癌の処置におけるマイグラスタチンアナログ
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
EP1797877A4 (en) 2004-09-13 2010-12-15 Eisai Co Ltd JOINT USE OF A SULFONAMIDE-BASED COMPOUND AND AN ANGIOGENESIS INHIBITOR
US8188141B2 (en) * 2004-09-23 2012-05-29 Sloan-Kettering Institute For Cancer Research Isomigrastatin analogs in the treatment of cancer
JPWO2006090930A1 (ja) 2005-02-28 2008-07-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド化合物の新規併用
JP5094394B2 (ja) * 2005-04-20 2012-12-12 武田薬品工業株式会社 縮合複素環化合物
EP1932841B1 (en) * 2005-08-30 2014-01-01 Asahi Kasei Pharma Corporation Sulfonamide compound
CN101360422B (zh) * 2005-11-23 2013-10-23 得克萨斯大学体系董事会 致癌Ras特异性细胞毒化合物及其使用方法
US7625896B2 (en) * 2005-11-25 2009-12-01 Hoffman-La Roche Inc. Pyridylsulfonamide derivatives
WO2007086605A1 (ja) * 2006-01-27 2007-08-02 Eisai R & D Management Co., Ltd. スルホンアミド化合物の効果を予測する方法
JPWO2007123274A1 (ja) 2006-04-20 2009-09-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド化合物の新規感受性マーカー
DE102007012284A1 (de) * 2007-03-16 2008-09-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007035334A1 (de) 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007035333A1 (de) 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007042154A1 (de) 2007-09-05 2009-03-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Arylsulfonylaminomethyphosphonsäure-Derivate, deren Herstellung und deren Verwendung als Arzneimittel
US20090142832A1 (en) * 2007-11-29 2009-06-04 James Dalton Indoles, Derivatives, and Analogs Thereof and Uses Therefor
JP2012136435A (ja) * 2009-03-30 2012-07-19 Eisai R & D Management Co Ltd 腫瘍組織の感受性を検査する方法
EP2817292B1 (en) 2012-02-22 2019-12-18 Sanford-Burnham Medical Research Institute Sulfonamide compounds and uses as tnap inhibitors
CN104098498A (zh) * 2014-07-30 2014-10-15 天津市斯芬克司药物研发有限公司 一种吲唑类化合物及其制备方法
US11072583B2 (en) 2017-11-27 2021-07-27 Council Of Scientific & Industrial Research Indole (sulfomyl) n-hydroxy benzamide derivatives as selective HDAC inhibitors
JP2021511290A (ja) * 2018-01-25 2021-05-06 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド タンパク質分解のためのスルホンアミド誘導体
WO2020210139A1 (en) * 2019-04-10 2020-10-15 Peloton Therapeutics, Inc. Pyrazolesulfonamides as antitumor agents
EP4573088A1 (en) * 2022-08-15 2025-06-25 Recursion Pharmaceuticals, Inc. Heterocycle rbm39 modulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9115160D0 (en) * 1991-07-12 1991-08-28 Erba Carlo Spa Methylen-oxindole derivatives and process for their preparation
US5169860A (en) * 1992-03-13 1992-12-08 Eli Lilly And Company Antitumor compositions and methods of treatment
ZA941500B (en) * 1993-03-10 1995-09-04 Lilly Co Eli Antitumor compositions and methods of treatment
PT673937E (pt) * 1993-09-10 2004-04-30 Eisai Co Ltd Derivados biciclicos heterociclicos de sulfonamida e de ester sulfonico
JP3545461B2 (ja) * 1993-09-10 2004-07-21 エーザイ株式会社 二環式ヘテロ環含有スルホンアミド誘導体
JP3690831B2 (ja) * 1995-02-27 2005-08-31 エーザイ株式会社 インドール含有スルホンアミド誘導体
JP4130700B2 (ja) * 1996-02-26 2008-08-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗腫瘍剤含有組成物
JP3868534B2 (ja) * 1996-05-24 2007-01-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド誘導体の製造法および中間体
KR100767000B1 (ko) 2000-02-03 2007-10-15 에자이 알앤드디 매니지먼트 가부시키가이샤 인테그린 발현 저해제

Also Published As

Publication number Publication date
CA2327253A1 (en) 2000-08-31
HUP0101434A3 (en) 2001-10-29
US6638964B2 (en) 2003-10-28
WO2000050395A1 (en) 2000-08-31
RU2208607C2 (ru) 2003-07-20
US20020128483A1 (en) 2002-09-12
NO317299B1 (no) 2004-10-04
US6469043B1 (en) 2002-10-22
JP3866041B2 (ja) 2007-01-10
AU766936B2 (en) 2003-10-23
JP2010180229A (ja) 2010-08-19
EP1074542A4 (en) 2002-02-06
AU2691600A (en) 2000-09-14
KR100627611B1 (ko) 2006-09-25
CN1294579A (zh) 2001-05-09
KR20010042434A (ko) 2001-05-25
ATE325094T1 (de) 2006-06-15
EP1074542B1 (en) 2006-05-03
HU228787B1 (en) 2013-05-28
EP1074542A1 (en) 2001-02-07
JP2000247949A (ja) 2000-09-12
US20020128480A1 (en) 2002-09-12
DK1074542T3 (da) 2006-08-14
DE60027648D1 (de) 2006-06-08
ES2259997T3 (es) 2006-11-01
DE60027648T2 (de) 2007-04-05
PT1074542E (pt) 2006-07-31
NO20005357L (no) 2000-12-22
US6673787B2 (en) 2004-01-06
NZ507464A (en) 2003-10-31
CA2327253C (en) 2007-10-16
CN1132814C (zh) 2003-12-31
HUP0101434A2 (hu) 2001-09-28

Similar Documents

Publication Publication Date Title
DK1074542T3 (da) Sulfonamidholdige indolforbindelser
NZ514873A (en) 4,5,6,7-tetrahydroindazole derivatives as antitumor agents
ATE129714T1 (de) Heterocyclische biphosphonsäurederivate.
NZ336302A (en) Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia
DK0749424T3 (da) Naphthalenderivater som prostaglandin-I2-agonister
EA200401056A1 (ru) Комбинация, содержащая производные тропана, полезные в терапии
DK0928788T3 (da) Imidazolidin-4-on-derivater, der er nyttige som anticancer-midler
DE60140456D1 (de) Aza heterocyclische derivate und ihre therapeutische verwendung
DE69609325D1 (de) Derivate des radicicols
DE69312243D1 (de) Phenoxy- oder Phenoxyalkyl-Piperidine als antivirale Mittel
CA2134077A1 (en) 4-imidomethyl-1-[2'phenyl-2'oxoethyl-]piperidines as serotonin 5ht2-antagonists, their preparation and use in therapy
ATE233242T1 (de) Chinoline und chinazoline verbindungen und ihre therapeutische anwendung
NZ221699A (en) Pyridazinone derivatives; pharmaceutical compositions and intermediates
NO961797L (no) Anvendelse av benzopyranderivater for fremstilling av farmasöytiske sammensetninger beregnet for behandling av patologier forbundet med den Na+-uavhengige C1-HCO3-utbytter
HRP20010885B1 (en) Ethanesulfonyl-piperidine derivatives
DK1163258T3 (da) Derivater af 22R-hydroxycholesta-8, 14-dien til inhiberingen af meiosis
MEP12408A (en) Acyloxypyrrolidine derivatives and use thereof as ligands of v1b or both v1b and v1a receptors
HUP9902270A1 (hu) Analgetikus hatású akridinszármazékok, előállításuk és alkalmazásuk
ES472591A1 (es) Procedimiento para la obtencion de derivados de 1-fenileta- nolamina
EP0254527A3 (en) New tetracyclic indole derivatives
ES2182775T3 (es) Derivados de ciclohexano 1,4-disustituidos para el tratamiento de la depresion.
ECSP993005A (es) Compuestos de sulfonilbenceno como agentes anti-inflamatorios / analgesicos

Legal Events

Date Code Title Description
ERR Erratum

Free format text: SULFONAMIDHOLDIGE INDOLFORBINDELSER, DERES ANVENDELSE SAMT FARMASOYTISKE PREPARATER INNEHOLDENDE DISSE

MM1K Lapsed by not paying the annual fees